Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
LetterLetter

Acute Myocarditis in Patients with Antineutrophil Cytoplasmic Antibody–positive Microscopic Polyangiitis and Receiving Rituximab Therapy

CHRONG-REEN WANG, YI-SHAN TSAI and HUNG-WEN TSAI
The Journal of Rheumatology December 2019, 46 (12) 1645-1646; DOI: https://doi.org/10.3899/jrheum.190569
CHRONG-REEN WANG
Department of Internal Medicine;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for CHRONG-REEN WANG
  • For correspondence: wangcr@mail.ncku.edu.tw
YI-SHAN TSAI
Department of Medical Imaging;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HUNG-WEN TSAI
Department of Pathology, National Cheng Kung University Hospital, Tainan, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

The presence of cardiac insufficiency is recognized as a poor prognostic factor in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)1, and heart failure is an identified mortality risk factor for eosinophilic granulomatosis with polyangiitis (EGPA)2. Microscopic polyangiitis (MPA) has lower frequencies of myocardial involvement with rarely reported acute myocarditis presentation3. Rituximab (RTX) is a first-line induction therapy licensed for severe MPA with reduced ANCA titers and clinical remission4. In this study, we reviewed hospitalized patients with MPA who were receiving RTX therapy for acute myocarditis-related heart failure.

A retrospective study was carried out at the National Cheng Kung University Hospital from January 2014 to December 2018. Hospitalized patients fulfilling the 2012 Revised Chapel Hill Consensus Conference MPA definition5 were analyzed under the permission of the institutional review board (approval no. B-ER-105-108). Acute myocarditis was defined as (1) symptoms such as fever, dyspnea, orthopnea, chest pain, and palpitation; (2) raised cardiac biomarker levels; and (3) new/worsening echocardiograph or cardiac magnetic resonance imaging (cMRI) changes including wall motion abnormalities and impaired left ventricular ejection fraction (LVEF)6,7, excluding myocardial dysfunction attributed to coronary artery disease and viral myocarditis. Data were expressed as mean and SD.

Ten patients fulfilled the MPA definition, with 5 males aged 34–78 years (60.2 ± 14.6). At disease onset, all had myeloperoxidase (MPO) antibody, and Birmingham Vasculitis Activity Score (BVAS)8 17 to 39 (26 ± 6) and 5-factor score (FFS)1 1 to 3 (1.9 ± 0.7). Medications and procedures included corticosteroid (CS) or plus pulse methylprednisolone, cyclophosphamide (CYC), RTX, and plasma exchange for induction therapy, and CS and azathioprine (AZA) for maintenance treatment.

Three males had acute myocarditis. They were aged 53 to 82 years (66.3 ± 14.6), and all had acute myocarditis as a later development, 1 to 13 years (7.3 ± 6.0) after the disease onset (Table 1). BVAS was 26 to 30 (28 ± 2) and FFS 2 or 3 (2.7 ± 0.6). In addition to proteinuria and microscopic hematuria, cases 1 and 2 had impaired estimated glomerular filtration rate (eGFR). All had parenchymal lung involvement, with diffuse alveolar hemorrhage (DAH) in case 1.

View this table:
  • View inline
  • View popup
Table 1.

Clinical/medication data of MPA myocarditis before and after RTX therapy.

There were myocarditis-related symptoms with New York Heart Association Functional Classification (NYHAFC) II to IV and elevated anti-MPO and cardiac troponin I levels before the RTX therapy. The medications before prescribing RTX were CYC and CS for induction in case 1. Cases 2 and 3 received initial induction with CYC and CS at the disease diagnosis, followed by AZA and CS maintenance. The indications for RTX were refractory disease in case 1 and relapse activity in cases 2 and 3 with a regimen of 375 mg/m2 weekly × 4, resulting in a complete B cell depletion (0/μl). In addition to absent anti-MPO and lower BVAS (7.0 ± 2.6), all had decreased NYHAFC to I after the RTX therapy. Besides LV enlargement, there were global hypokinesia/impaired LVEF in echocardiograph before the usage, and normalized LVEF without chamber enlargement/hypokinesia after the therapy. The cMRI revealed myocarditis-related late gadolinium enhancement (LGE) in global LV mid-wall myocardium or plus epicardium in cases 1 and 2, and pericarditis with enhanced thick pericardium in case 1 (Figure 1A). LV endocarditis with perfusion defects was identified in cases 1 and 2. Followup cMRI in case 1 revealed completely resolved LGE at LV myocardium and lessened pericardial enhancement (Figure 1B).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Serial cMRI images of case 1. A. Pre-RTX treatment cMRI late gadolinium enhancement (LGE) image shows pericarditis with enhanced thick pericardium (white arrows) and acute myocardial edema with linear LGE (white hollow arrows). B. Post-RTX treatment image discloses completely resolved myocardial edema and lessened pericardial enhancement. cMRI: cardiac magnetic resonance imaging; RTX: rituximab.

Nonspecific complaint in acute myocarditis such as dyspnea or chest pain is an underdiagnosed cause of acute heart failure7. Despite common presentation in admitted patients from this study, acute myocarditis has scarcely been reported in MPA3, raising the possibility of an overlooked diagnosis. The myocarditis-associated heart failure in MPA can have clinical symptoms and physical signs such as dyspnea and pedal edema mimicking the lung and renal involvement, respectively. Further, myocarditis is not included among initial manifestations before the diagnosis of MPA but as a later development during longterm followup, as demonstrated in our cases. Indeed, the acute myocarditis might not be as rare as previously reported in the patients with MPA, and a survey echocardiograph could help to detect such a critical manifestation.

MPO antibody is an activity marker correlated with BVAS and a predictor of relapse in MPA9. Pathogenic roles of B cells in MPA are highlighted by the association of B cell activation with disease activity and the therapeutic efficacy of depleting B cells10. Activated B cells can serve as precursors of ANCA-producing plasma cells, and can present autoantigens and provide co-stimulatory signals to autoreactive T cells. B cell depletion with reduced ANCA titers by the RTX usage is an effective CYC alternative for the induction of clinical remission4. In this study, after the RTX therapy with complete depletion of B cells, all patients had no MPO antibody, resulting in clinical improvement with reduced BVAS and a recovery of myocardial dysfunction.

Acknowledgment

The authors are indebted to Prof. Ming-Fei Liu and other doctors and nurses involved in the diagnosis and management of reported patients at the National Cheng Kung University Hospital.

REFERENCES

  1. 1.↵
    1. Guillevin L,
    2. Pagnoux C,
    3. Seror R,
    4. Mahr A,
    5. Mouthon L,
    6. Le Toumelin P,
    7. et al.
    The Five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 2011;90:19–27.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Moosig F,
    2. Bremer JP,
    3. Hellmich B,
    4. Holle JU,
    5. Holl-Ulrich K,
    6. Laudien M,
    7. et al.
    A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013;72:1011–7.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Misra DP,
    2. Shenoy SN
    . Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int 2017;37:151–67.
    OpenUrl
  4. 4.↵
    1. Lally L,
    2. Spiera R
    . Current therapies for ANCA-associated vasculitis. Annu Rev Med 2015;66:227–40.
    OpenUrl
  5. 5.↵
    1. Jennette JC,
    2. Falk RJ,
    3. Bacon PA,
    4. Basu N,
    5. Cid MC,
    6. Ferrario F,
    7. et al.
    2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1–11.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Wang CR,
    2. Tsai YS,
    3. Li WT
    . Lupus myocarditis receiving the rituximab therapy-a monocentric retrospective study. Clin Rheumatol 2018;37:1701–7.
    OpenUrl
  7. 7.↵
    1. Sagar S,
    2. Liu PP,
    3. Cooper LT Jr
    Myocarditis. Lancet 2012;379:738–47.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Mukhtyar C,
    2. Lee R,
    3. Brown D,
    4. Carruthers D,
    5. Dasgupta B,
    6. Dubey S,
    7. et al.
    Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827–32.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Terrier B,
    2. Saadoun D,
    3. Sène D,
    4. Ghillani P,
    5. Amoura Z,
    6. Deray G,
    7. et al.
    Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 2009;68:1564–71.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. McClure M,
    2. Gopaluni S,
    3. Jayne D,
    4. Jones R
    . B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol 2018;14:580–91.
    OpenUrl
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 12
1 Dec 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Acute Myocarditis in Patients with Antineutrophil Cytoplasmic Antibody–positive Microscopic Polyangiitis and Receiving Rituximab Therapy
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
Citation Tools
Acute Myocarditis in Patients with Antineutrophil Cytoplasmic Antibody–positive Microscopic Polyangiitis and Receiving Rituximab Therapy
CHRONG-REEN WANG, YI-SHAN TSAI, HUNG-WEN TSAI
The Journal of Rheumatology Dec 2019, 46 (12) 1645-1646; DOI: 10.3899/jrheum.190569

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Acute Myocarditis in Patients with Antineutrophil Cytoplasmic Antibody–positive Microscopic Polyangiitis and Receiving Rituximab Therapy
CHRONG-REEN WANG, YI-SHAN TSAI, HUNG-WEN TSAI
The Journal of Rheumatology Dec 2019, 46 (12) 1645-1646; DOI: 10.3899/jrheum.190569
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • To the Editor:
    • Acknowledgment
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • A Case of Minimal Change Disease in a Patient with Rheumatoid Arthritis Treated with Certolizumab
  • The Performance of Psoriatic Arthritis Screening Questionnaires in Patients with Psoriasis
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • AV Rheum

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire